- Conditions
- Painful Diabetic Peripheral Neuropathy
- Interventions
- VM202
- Biological
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Walnut Creek, California • Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Critical Limb Ischemia
- Interventions
- Low Dose VM202, High Dose VM202, Placebo
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more
- Conditions
- Critical Limb Ischemia
- Interventions
- VM202 2 mg, VM202 4 mg, VM202 8 mg, VM202 16 mg
- Biological
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
- Interventions
- Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
- Genetic · Drug
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
- Conditions
- Peripheral Artery Disease
- Interventions
- VM202, Placebo
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
- Interventions
- Engensis (VM202), placebo
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- VM-202
- Biological
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myocardial Ischemia
- Interventions
- VM202
- Biological
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 21 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- VM202
- Biological
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- Engensis (VM202), Placebo
- Genetic · Drug
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- Painful Diabetic Neuropathies
- Interventions
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more